Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
GlaxoSmithKline, Cambridge, MA, USA.
Cephalalgia. 2022 Apr;42(4-5):345-356. doi: 10.1177/03331024211045651. Epub 2021 Oct 14.
Migraine is diagnosed using the extensively field-tested International Classification of Headache Disorders (ICHD-3) consensus criteria derived by the International Headache Society. To evaluate the criteria in respect to a measurable biomarker, we studied the relationship between the main ICHD-3 criteria and the polygenic risk score, a measure of common variant burden in migraine.
We used linear mixed models to study the correlation of ICHD-3 diagnostic criteria, underlying symptoms, and main diagnoses with the polygenic risk score of migraine in a cohort of 8602 individuals from the Finnish Migraine Genome Project.
Main diagnostic categories and all underlying diagnostic criteria formed a consistent continuum along the increasing polygenic burden. Polygenic risk was associated with the heterogeneous clinical picture starting from the non-migraine headache (mean 0.07; 95% CI 0.02-0.12; = 0.008 compared to the non-headache group), to probable migraine (mean 0.13; 95% CI 0.08-0.18; < 0.001), migraine headache (mean 0.17; 95% CI 0.14-0.21; < 0.001) and migraine with typical visual aura (mean 0.29; 95% CI 0.26-0.33; < 0.001), all the way to the hemiplegic aura (mean 0.37; 95% CI 0.31-0.43; < 0.001). All individual ICHD-3 symptoms and the total number of reported symptoms, a surrogate of migraine complexity, demonstrated a clear inclination with an increasing polygenic risk.
The complex migraine phenotype progressively follows the polygenic burden from individuals with no headache to non-migrainous headache and up to patients with attacks manifesting all the features of the ICHD-3 headache and aura. Results provide further biological support for the ICHD-3 diagnostic criteria.
偏头痛的诊断采用的是经过广泛实地测试的国际头痛疾病分类(ICHD-3)共识标准,该标准由国际头痛协会制定。为了评估该标准在可衡量生物标志物方面的表现,我们研究了 ICHD-3 的主要标准与多基因风险评分之间的关系,该评分是偏头痛常见变异负担的衡量标准。
我们使用线性混合模型,研究了芬兰偏头痛基因组计划中的 8602 名个体中,ICHD-3 诊断标准、潜在症状和主要诊断与偏头痛多基因风险评分之间的相关性。
主要诊断类别和所有潜在诊断标准沿着不断增加的多基因负担形成了一个一致的连续体。多基因风险与从非偏头痛性头痛(平均 0.07;95%CI 0.02-0.12;与非头痛组相比, = 0.008)开始的异质临床特征相关,到可能的偏头痛(平均 0.13;95%CI 0.08-0.18; < 0.001)、偏头痛头痛(平均 0.17;95%CI 0.14-0.21; < 0.001)和典型视觉先兆偏头痛(平均 0.29;95%CI 0.26-0.33; < 0.001),一直到偏瘫性先兆偏头痛(平均 0.37;95%CI 0.31-0.43; < 0.001)。所有 ICHD-3 症状和报告的症状总数,偏头痛复杂性的替代指标,都表现出随着多基因风险的增加而明显倾斜的趋势。
复杂的偏头痛表型逐渐遵循多基因负担,从没有头痛的个体到非偏头痛性头痛,再到表现出 ICHD-3 头痛和先兆所有特征的患者。结果为 ICHD-3 诊断标准提供了进一步的生物学支持。